Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
9
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 9 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Cinvanti Aprepitant · J0185 | B | $42.3M | +5% | 40,602 | $1,041 | $1.69 |
| Aprepitant Aprepitant | D | $8.1M | -7% | 5,483 | $1,470 | $96.14 |
| Emend* Fosaprepitant Dimeglumine* · J1453 | B | $2.2M | -9% | 21,354 | $103 | $0.14 |
| Fosaprepitant Dimeglumine Fosaprepitant Dimeglumine | D | $520K | +10% | 720 | $722 | $83.66 |
| Cinvanti Aprepitant | D | $289K | +104% | 149 | $1,939 | $23.15 |
| Fosaprepitant Dimeglumine Fosaprepitant Dimeglumine · J1456 | B | $275K | +183% | 533 | $517 | $1.30 |
| Emend Aprepitant | D | $123K | +100% | 15 | $8,193 | $253.51 |
| Emend Fosaprepitant Dimeglumine | D | $7K | n/a | n/a | n/a | $193.54 |
| Aprepitant* Aprepitant* · J8501 | B | $1K | -50% | n/a | n/a | $3.45 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.